Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response
Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response. There were 61 patients wi...
Saved in:
| Published in: | Journal of rheumatology Vol. 43; no. 8; p. 1566 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Canada
01.08.2016
|
| Subjects: | |
| ISSN: | 0315-162X, 1499-2752, 1499-2752 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response.
There were 61 patients with Jo1 antisynthetase syndrome identified; 18 of these received RTX. One patient was lost to followup. The remaining 17 patients and 30 out of 43 patients who were treated with conventional immunosuppressive (IS) drugs were followed for a mean of 35 months and 84 months, respectively.
Polymyositis/dermatomyositis (95%) and interstitial lung disease (ILD; 66%) were the dominant clinical manifestations. Detection of anti-Ro52 antibodies (43%) was significantly associated with acute-onset ILD (p = 0.016) with O2 dependency, and patients with high concentrations of anti-Ro52 (20%) had the highest risk (p = 0.0005). Sixteen out of 18 patients (89%) showed a fast and marked response to RTX. Among those patients who were highly positive for anti-Ro52, response to RTX was seen in 7 out of 7 cases (100%), but no response to cyclophosphamide (n = 4), cyclosporine A (n = 3), azathioprine (n = 9), methotrexate (n = 5), or leflunomide (n = 2) was observed. One patient treated with RTX died of pneumonia.
RTX is effective in the treatment of severe forms of Jo1 antisynthetase syndrome. In our retrospective study, the presence of high anti-Ro52 antibody concentrations predicts severe acute-onset ILD and nonresponse to IS drugs. In contrast to conventional IS, RTX is equally effective in patients with Jo1 antisynthetase syndrome, independent of their anti-Ro52 antibody status. |
|---|---|
| AbstractList | Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response.
There were 61 patients with Jo1 antisynthetase syndrome identified; 18 of these received RTX. One patient was lost to followup. The remaining 17 patients and 30 out of 43 patients who were treated with conventional immunosuppressive (IS) drugs were followed for a mean of 35 months and 84 months, respectively.
Polymyositis/dermatomyositis (95%) and interstitial lung disease (ILD; 66%) were the dominant clinical manifestations. Detection of anti-Ro52 antibodies (43%) was significantly associated with acute-onset ILD (p = 0.016) with O2 dependency, and patients with high concentrations of anti-Ro52 (20%) had the highest risk (p = 0.0005). Sixteen out of 18 patients (89%) showed a fast and marked response to RTX. Among those patients who were highly positive for anti-Ro52, response to RTX was seen in 7 out of 7 cases (100%), but no response to cyclophosphamide (n = 4), cyclosporine A (n = 3), azathioprine (n = 9), methotrexate (n = 5), or leflunomide (n = 2) was observed. One patient treated with RTX died of pneumonia.
RTX is effective in the treatment of severe forms of Jo1 antisynthetase syndrome. In our retrospective study, the presence of high anti-Ro52 antibody concentrations predicts severe acute-onset ILD and nonresponse to IS drugs. In contrast to conventional IS, RTX is equally effective in patients with Jo1 antisynthetase syndrome, independent of their anti-Ro52 antibody status. Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response.OBJECTIVERituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response.There were 61 patients with Jo1 antisynthetase syndrome identified; 18 of these received RTX. One patient was lost to followup. The remaining 17 patients and 30 out of 43 patients who were treated with conventional immunosuppressive (IS) drugs were followed for a mean of 35 months and 84 months, respectively.METHODSThere were 61 patients with Jo1 antisynthetase syndrome identified; 18 of these received RTX. One patient was lost to followup. The remaining 17 patients and 30 out of 43 patients who were treated with conventional immunosuppressive (IS) drugs were followed for a mean of 35 months and 84 months, respectively.Polymyositis/dermatomyositis (95%) and interstitial lung disease (ILD; 66%) were the dominant clinical manifestations. Detection of anti-Ro52 antibodies (43%) was significantly associated with acute-onset ILD (p = 0.016) with O2 dependency, and patients with high concentrations of anti-Ro52 (20%) had the highest risk (p = 0.0005). Sixteen out of 18 patients (89%) showed a fast and marked response to RTX. Among those patients who were highly positive for anti-Ro52, response to RTX was seen in 7 out of 7 cases (100%), but no response to cyclophosphamide (n = 4), cyclosporine A (n = 3), azathioprine (n = 9), methotrexate (n = 5), or leflunomide (n = 2) was observed. One patient treated with RTX died of pneumonia.RESULTSPolymyositis/dermatomyositis (95%) and interstitial lung disease (ILD; 66%) were the dominant clinical manifestations. Detection of anti-Ro52 antibodies (43%) was significantly associated with acute-onset ILD (p = 0.016) with O2 dependency, and patients with high concentrations of anti-Ro52 (20%) had the highest risk (p = 0.0005). Sixteen out of 18 patients (89%) showed a fast and marked response to RTX. Among those patients who were highly positive for anti-Ro52, response to RTX was seen in 7 out of 7 cases (100%), but no response to cyclophosphamide (n = 4), cyclosporine A (n = 3), azathioprine (n = 9), methotrexate (n = 5), or leflunomide (n = 2) was observed. One patient treated with RTX died of pneumonia.RTX is effective in the treatment of severe forms of Jo1 antisynthetase syndrome. In our retrospective study, the presence of high anti-Ro52 antibody concentrations predicts severe acute-onset ILD and nonresponse to IS drugs. In contrast to conventional IS, RTX is equally effective in patients with Jo1 antisynthetase syndrome, independent of their anti-Ro52 antibody status.CONCLUSIONRTX is effective in the treatment of severe forms of Jo1 antisynthetase syndrome. In our retrospective study, the presence of high anti-Ro52 antibody concentrations predicts severe acute-onset ILD and nonresponse to IS drugs. In contrast to conventional IS, RTX is equally effective in patients with Jo1 antisynthetase syndrome, independent of their anti-Ro52 antibody status. |
| Author | Bauhammer, Jutta Wagner, Ulrich Fiehn, Christoph Krause, Dietmar Blank, Norbert Max, Regina Lorenz, Hanns-Martin |
| Author_xml | – sequence: 1 givenname: Jutta surname: Bauhammer fullname: Bauhammer, Jutta organization: From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases – sequence: 2 givenname: Norbert surname: Blank fullname: Blank, Norbert organization: From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases – sequence: 3 givenname: Regina surname: Max fullname: Max, Regina organization: From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases – sequence: 4 givenname: Hanns-Martin surname: Lorenz fullname: Lorenz, Hanns-Martin organization: From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases – sequence: 5 givenname: Ulrich surname: Wagner fullname: Wagner, Ulrich organization: From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases – sequence: 6 givenname: Dietmar surname: Krause fullname: Krause, Dietmar organization: From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases – sequence: 7 givenname: Christoph surname: Fiehn fullname: Fiehn, Christoph email: c.fiehn@acura-kliniken.com organization: From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. c.fiehn@acura-kliniken.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27252419$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LAzEYhIMo2qpHr5Kjl9Ukm2QTbyJ-oiitgreS3byL0W5Sk2xxf4d_2FIVPA3MPMzAjNGmDx4QOqDkuFRan7zFV-i7YyqI4nwDjSjXumCVYJtoREoqCirZyw4ap_RGCJVcqm20wyomGKd6hL4mLvefrjM1dh7nV8BPEUzuwGccWnwbKD7z2dXBDoVJKTTOZLBrLw1-xWeTAE8Hb2Po4HQdFJMgGH4MyWW3dHnAJmGD7018h4jbEPEUlhDXgbf_9iaQFsEn2ENbrZkn2P_VXfR8efF0fl3cPVzdnJ_dFQ1nOhemltRKKwUljWhr1UrFraLSGluxRgArWSW1aMGWlSkbznXFlbBEl5JpYSnbRUc_vYsYPnpIeda51MB8bjyEPs2oIkqSUmi2Qg9_0b7uwM4WcXVZHGZ_R7JvV5h5Bg |
| CitedBy_id | crossref_primary_10_1007_s13665_025_00383_2 crossref_primary_10_1055_a_1853_1766 crossref_primary_10_1007_s11926_018_0731_7 crossref_primary_10_1016_j_jaut_2021_102774 crossref_primary_10_1007_s40674_021_00177_y crossref_primary_10_1177_09612033221122158 crossref_primary_10_1016_j_rmed_2016_12_014 crossref_primary_10_1080_07853890_2024_2440621 crossref_primary_10_1038_s41572_021_00321_x crossref_primary_10_3390_biom15050643 crossref_primary_10_1080_14740338_2021_1973428 crossref_primary_10_1016_j_semarthrit_2021_05_019 crossref_primary_10_1016_j_rdc_2025_07_002 crossref_primary_10_1016_j_autrev_2017_07_016 crossref_primary_10_1093_rheumatology_keaa801 crossref_primary_10_1007_s00296_023_05336_z crossref_primary_10_1016_j_rdc_2024_03_007 crossref_primary_10_1080_1744666X_2023_2212162 crossref_primary_10_1055_s_0044_1785536 crossref_primary_10_3390_jcm13144055 crossref_primary_10_1016_j_rcreue_2023_11_002 crossref_primary_10_1007_s10405_022_00483_9 crossref_primary_10_1007_s00393_021_01067_3 crossref_primary_10_1016_j_coph_2022_102257 crossref_primary_10_1016_j_berh_2020_101503 crossref_primary_10_1016_j_jbspin_2025_105932 crossref_primary_10_1177_1759720X211032457 crossref_primary_10_3390_jcm9103070 crossref_primary_10_1097_BOR_0000000000000663 crossref_primary_10_1136_annrheumdis_2018_215004 crossref_primary_10_7759_cureus_15931 crossref_primary_10_1016_j_semarthrit_2017_06_004 crossref_primary_10_1007_s00296_019_04398_2 crossref_primary_10_3389_fimmu_2022_1051609 crossref_primary_10_1016_j_ard_2025_01_050 crossref_primary_10_1038_s41598_023_30595_y crossref_primary_10_1177_17534666251336896 crossref_primary_10_1016_j_clindermatol_2018_04_008 crossref_primary_10_1016_j_rmed_2025_108070 crossref_primary_10_1097_MCP_0000000000000508 crossref_primary_10_1016_j_rmed_2020_105983 crossref_primary_10_1002_rcr2_1141 crossref_primary_10_1002_emp2_12835 crossref_primary_10_1002_jcla_24045 crossref_primary_10_1097_BOR_0000000000000434 crossref_primary_10_1186_s12890_020_01335_z crossref_primary_10_1016_j_semarthrit_2025_152712 crossref_primary_10_1097_BOR_0000000000000432 crossref_primary_10_1002_iid3_1085 crossref_primary_10_3389_fimmu_2021_711102 crossref_primary_10_1177_2397198320902667 crossref_primary_10_1007_s40674_018_0111_5 crossref_primary_10_1186_s13075_024_03382_x crossref_primary_10_1080_17512433_2017_1353910 crossref_primary_10_1016_j_autrev_2021_103013 crossref_primary_10_1016_j_ccm_2019_05_004 crossref_primary_10_1016_j_ccm_2021_03_010 crossref_primary_10_1016_j_berh_2022_101762 crossref_primary_10_4081_mrm_2023_890 crossref_primary_10_1002_smtd_202301142 crossref_primary_10_1055_s_0044_1786155 crossref_primary_10_12890_2022_003324 crossref_primary_10_4103_ara_ara_10_25 crossref_primary_10_1038_nrrheum_2018_42 crossref_primary_10_1016_j_cellimm_2023_104776 crossref_primary_10_1093_rheumatology_keae403 crossref_primary_10_1007_s00393_019_0665_0 crossref_primary_10_1016_j_autrev_2022_103264 crossref_primary_10_1016_j_chest_2023_01_031 crossref_primary_10_1016_j_ejim_2021_04_020 crossref_primary_10_1080_17843286_2021_1872312 crossref_primary_10_1007_s10067_021_05590_1 crossref_primary_10_1097_BOR_0000000000000536 crossref_primary_10_3390_jcm9093033 crossref_primary_10_1007_s00393_017_0327_z crossref_primary_10_1007_s10067_020_05075_7 crossref_primary_10_3389_fimmu_2024_1435525 crossref_primary_10_1007_s40674_020_00139_w crossref_primary_10_1007_s00296_017_3718_1 crossref_primary_10_1093_rheumatology_keab488 crossref_primary_10_1080_14397595_2018_1467257 crossref_primary_10_1007_s13671_022_00375_4 crossref_primary_10_1016_j_berh_2019_03_012 crossref_primary_10_1007_s00296_023_05279_5 crossref_primary_10_3390_diagnostics13243621 crossref_primary_10_1136_bcr_2019_231006 crossref_primary_10_3389_fmed_2020_00011 crossref_primary_10_1016_j_autrev_2019_102453 crossref_primary_10_3390_ijms25084453 crossref_primary_10_1007_s00393_025_01700_5 crossref_primary_10_1016_j_semarthrit_2022_152088 crossref_primary_10_1007_s15002_020_2908_5 crossref_primary_10_1016_j_semarthrit_2024_152560 crossref_primary_10_1093_rheumatology_keaf287 crossref_primary_10_1002_14651858_CD015854 crossref_primary_10_3389_fimmu_2021_684699 crossref_primary_10_3389_fimmu_2019_00444 crossref_primary_10_1016_j_intimp_2021_107524 crossref_primary_10_1007_s12016_021_08911_z crossref_primary_10_1016_j_iac_2023_01_012 crossref_primary_10_2478_jtim_2022_0029 crossref_primary_10_1093_rheumatology_keaa786 crossref_primary_10_1016_j_autrev_2021_103016 crossref_primary_10_2147_IJGM_S315885 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3899/jrheum.150844 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1499-2752 |
| ExternalDocumentID | 27252419 |
| Genre | Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 123 18M 1KJ 3O- 4.4 53G 5RE 6PF AAFWJ AAQQT AAWTL ABCQX ABJNI ACGFO ACGFS ADCBC AENEX AFFNX AI. ALMA_UNASSIGNED_HOLDINGS BR6 CGR CUY CVF EBS ECM EIF EJD EMOBN F5P H13 HZ~ J5H L7B MJL NPM O9- P0W P2P RHI SJN TJE VH1 W2D X7M XBR XDU XOL YQJ ZGI ZXE ZXP 7X8 |
| ID | FETCH-LOGICAL-c429t-ab61d6d6510c5fb8f684d816dad72c5e2327695fed37a3c4497485d0936295d12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 116 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000380882300019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0315-162X 1499-2752 |
| IngestDate | Thu Oct 02 11:59:12 EDT 2025 Mon Jul 21 06:00:02 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | INTERSTITIAL LUNG DISEASE ANTISYNTHETASE ANTIBODIES Ro52 Jo1 POLYMYOSITIS |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c429t-ab61d6d6510c5fb8f684d816dad72c5e2327695fed37a3c4497485d0936295d12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 27252419 |
| PQID | 1808603592 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1808603592 pubmed_primary_27252419 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-08-01 |
| PublicationDateYYYYMMDD | 2016-08-01 |
| PublicationDate_xml | – month: 08 year: 2016 text: 2016-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | Journal of rheumatology |
| PublicationTitleAlternate | J Rheumatol |
| PublicationYear | 2016 |
| SSID | ssj0016468 |
| Score | 2.5226142 |
| Snippet | Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1566 |
| SubjectTerms | Adult Aged Autoantibodies - analysis Dermatomyositis - drug therapy Dermatomyositis - immunology Female Humans Immunosuppressive Agents - therapeutic use Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - immunology Male Middle Aged Myositis - drug therapy Myositis - immunology Retrospective Studies Ribonucleoproteins - immunology Rituximab - therapeutic use Severity of Illness Index Treatment Outcome Young Adult |
| Title | Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27252419 https://www.proquest.com/docview/1808603592 |
| Volume | 43 |
| WOSCitedRecordID | wos000380882300019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA5uiBf3fSGC12ibZvUigygiOgyjwtyGNElxhGl1FnF-h3_Yl7aDXgTBSw9NS8tb8r7kfXkPoRPKnPax1ySKbEqYlDExNtHg8ZlRVCuI2aWm72SzqTod3ao33IY1rXI6J5YTtSts2CM_ixWA71Bvjl68vpHQNSpkV-sWGrNoPgEoEyhdsvOdRRCsOgoHqJ5QyWlVYzNUlDt7GTz7cf80VENn7Hd0WUaZ65X__t8qWq7xJW5UBrGGZny-jhbv6wz6Bvps90bjj17fpLiXY0B_-HFKNcdFhm-LGDfyUS8t3ISYWnXelfeGkxyeH0HYww91nYPzcoC0C05xq6R_hVYU2AyxweEUkB9gAMX4wYPDlAO5-_G9dsXP9Zvo6frq8fKG1I0ZiIXwNSImFbETToA_W56lKhOKORULZ5yklntAaVJonnmXSJNYxmDRoriLNERLzV1Mt9BcXuR-B2FYYDrN0swnqWaKOm2TJDXciMgC0FDRLjqeirsLhh-yGSb3xXjY_Rb4LtqudNZ9rSp0dKmkHKCJ3vvD2_toCUCQqEh9B2g-A7f3h2jBvoNgB0elRcG12br_Aq2e11A |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rituximab+in+the+Treatment+of+Jo1+Antibody-associated+Antisynthetase+Syndrome%3A+Anti-Ro52+Positivity+as+a+Marker+for+Severity+and+Treatment+Response&rft.jtitle=Journal+of+rheumatology&rft.au=Bauhammer%2C+Jutta&rft.au=Blank%2C+Norbert&rft.au=Max%2C+Regina&rft.au=Lorenz%2C+Hanns-Martin&rft.date=2016-08-01&rft.issn=1499-2752&rft.eissn=1499-2752&rft.volume=43&rft.issue=8&rft.spage=1566&rft_id=info:doi/10.3899%2Fjrheum.150844&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0315-162X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0315-162X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0315-162X&client=summon |